To the full analysis
Medistim stock: growth
MEDI.OLMedistim reported $73.41M in revenue for fiscal 2025, up 24.4% on the prior year, up 14.5% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
10.9%
per year from 2006 to 2025, per share 11.2%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
15.8%
per year from 2006 to 2025, per share 16%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 14.5% | 10.8% | 10.9% |
| Revenue per share | 14.4% | 10.7% | 11.2% |
| Earnings | 18.1% | 14.7% | no data |
| Earnings per share | 18.0% | 14.6% | 12.4% |
| Free cash flow | 23.4% | 18.6% | 15.8% |
| Free cash flow per share | 23.3% | 18.5% | 16.0% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $10.24M | $0 | $1.18M |
| 2007 | $13.31M | $2.98M | $1.4M |
| 2008 | $14.72M | $1.42M | $1.84M |
| 2009 | $16.46M | $2.92M | $3.44M |
| 2010 | $16.45M | $1.96M | $3.39M |
| 2011 | $16.74M | $1.62M | $1.4M |
| 2012 | $19.09M | $3.17M | $2.07M |
| 2013 | $19.97M | $2.78M | $440.18K |
| 2014 | $22.48M | $3.28M | $3.62M |
| 2015 | $26.22M | $4.24M | $3.45M |
| 2016 | $27.56M | $4.1M | $1.79M |
| 2017 | $31.06M | $4.99M | $4.79M |
| 2018 | $33.89M | $5.99M | $4.14M |
| 2019 | $37.44M | $7.38M | $7M |
| 2020 | $37.37M | $7.28M | $6.66M |
| 2021 | $43.83M | $9.54M | $12.24M |
| 2022 | $51.01M | $11.96M | $9.69M |
| 2023 | $54.67M | $10.89M | $8.76M |
| 2024 | $59.02M | $10.89M | $14.38M |
| 2025 | $73.41M | $16.7M | $19.05M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = NOK 9.5325)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 22 Nov 2024)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.